BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
Saved in:
| Title: | BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. |
|---|---|
| Authors: | Schneider BP; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Jiang G; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Ballinger TJ; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Shen F; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Chitambar C; Medical College of Wisconsin, Milwaukee, WI., Nanda R; University of Chicago, Chicago, IL., Falkson C; University of Alabama at Birmingham, Birmingham, AL., Lynce FC; Georgetown University, Washington, DC., Gallagher C; Georgetown University, Washington, DC., Isaacs C; Georgetown University, Washington, DC., Blaya M; Memorial Healthcare System, Hollywood, FL., Paplomata E; Winship Cancer Institute of Emory University, Atlanta, GA., Walling R; Community Regional Cancer Care, Indianapolis, IN., Daily K; University of Florida, Gainesville, FL., Mahtani R; Sylvester Comprehensive Cancer Center, Deerfield Beach, FL., Thompson MA; Advocate Aurora Health, Milwaukee, WI., Graham R; Erlanger Health System, Chattanooga, TN., Cooper ME; Foundation Medicine Inc, Cambridge, MA., Pavlick DC; Foundation Medicine Inc, Cambridge, MA., Albacker LA; Foundation Medicine Inc, Cambridge, MA., Gregg J; Foundation Medicine Inc, Cambridge, MA.; University of California at Davis, Sacramento, CA., Solzak JP; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Chen YH; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Bales CL; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Cantor E; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Hancock BA; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Kassem N; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Helft P; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., O'Neil B; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Storniolo AMV; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Badve S; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Miller KD; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Radovich M; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN. |
| Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Feb 01; Vol. 40 (4), pp. 345-355. Date of Electronic Publication: 2021 Dec 15. |
| Publication Type: | Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
